The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.